UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 85

Sortiert nach

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Diabetes care, 2014-08, Vol.37 (8), p.2149-2158

2014

Link zum Volltext

Verfügbarkeit prüfen

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2021-02, Vol.106 (2), p.388-396

2021

Link zum Volltext

Verfügbarkeit prüfen

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

The Lancet (British edition), 2015-05, Vol.385 (9982), p.2057-2066

2015

Link zum Volltext

Verfügbarkeit prüfen

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell metabolism, 2022-09, Vol.34 (9), p.1234-1247.e9

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Diabetes care, 2009-03, Vol.32 (3), p.381-386

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Diabetes care, 2017-05, Vol.40 (5), p.647-654

2017

Link zum Volltext

Verfügbarkeit prüfen

Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

Diabetes care, 2011-07, Vol.34 (7), p.1511-1513

2011

Link zum Volltext

Verfügbarkeit prüfen

The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes

BMJ open diabetes research & care, 2022-08, Vol.10 (4), p.e002890

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Tirzepatide on Food Intake in Humans

Obesity (Silver Spring, Md.), 2022-11, Vol.30, p.48-49

2022

Link zum Volltext

Verfügbarkeit prüfen

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

The Lancet (British edition), 2023-08, Vol.402 (10401), p.529-544

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Diabetes care, 2021-03, Vol.44 (3), p.765-773

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

The lancet. Diabetes & endocrinology, 2022-06, Vol.10 (6), p.418-429

2022

Link zum Volltext

Verfügbarkeit prüfen

Retatrutide-Induced Weight Loss is Associated with Body Composition Improvements

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.241-242

2023

Link zum Volltext

Verfügbarkeit prüfen

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

The Lancet (British edition), 2022-11, Vol.400 (10366), p.1869-1881

2022

Link zum Volltext

Verfügbarkeit prüfen

P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation

Collegium antropologicum, 2013-06, Vol.37 (2), p.491-498

2013

Link zum Volltext

Verfügbarkeit prüfen

Sex, Age and BMI Predict Weight Loss Response to the GIP/GLP-1/Glucagon Receptor Agonist Retatrutide

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.27-27

2023

Link zum Volltext

Verfügbarkeit prüfen

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1024-1031

2017

Link zum Volltext

Verfügbarkeit prüfen

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

The lancet. Diabetes & endocrinology, 2018-05, Vol.6 (5), p.370-381

2018

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Diabetes care, 2023-05, Vol.46 (5), p.998-1004

2023

Link zum Volltext

Verfügbarkeit prüfen

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

Diabetes, obesity & metabolism, 2016-10, Vol.18 (10), p.999-1005

2016

Link zum Volltext

Verfügbarkeit prüfen

1611-P: Assessment of Fatty Acid Uptake by PET/MRI Imaging Under Fasting and Postprandial Conditions—A Repeatability Study in People with T2DM and Obesity

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(84)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Humans
(39)
Endocrinology & Metabolism
(34)
Diabetes
(33)
Diabetes Mellitus, Type 2 - Drug Therapy
(25)
Female
(24)
Male
(24)
Middle Aged
(23)
Diabetes Mellitus
(20)
Aged
(18)
Insulin
(18)
Hypoglycemic Agents - Therapeutic Use
(16)
Type 2 Diabetes
(16)
Glucagon
(14)
Diabetes Mellitus, Type 2 - Blood
(13)
Hypoglycemic Agents - Administration & Dosage
(13)
Adult
(12)
Treatment Outcome
(12)
Clinical Trials
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Diabetes
(14)
Diabetes Care
(12)
Diabetes, Obesity & Metabolism
(9)
Diabetes Research And Clinical Practice
(5)
Clinical Therapeutics
(4)
Obesity
(4)
The Lancet
(4)
Canadian Journal Of Diabetes
(3)
Medical Science Monitor
(3)
Collegium Antropologicum
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Effect of Tirzepatide on Food Intake in Humans

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Retatrutide-Induced Weight Loss is Associated with Body Composition Improvements

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation

Sex, Age and BMI Predict Weight Loss Response to the GIP/GLP-1/Glucagon Receptor Agonist Retatrutide

129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

1611-P: Assessment of Fatty Acid Uptake by PET/MRI Imaging Under Fasting and Postprandial Conditions—A Repeatability Study in People with T2DM and Obesity

Suchergebnisse filtern